Meeting
2019 ASCO Annual Meeting
A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN).
Authors
Binghe Xu
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, China
Binghe Xu , Wei Li , Qingyuan Zhang , Shao Zhimin , Wang Xiao Jia , Huiping Li , Tao Sun , Yongmei Yin , Hong Zheng , Hong Zhang , Tiffanie Chan , Guiyuan Lei , Eleonora Restuccia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT02896855
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1026)
DOI
10.1200/JCO.2019.37.15_suppl.1026
Abstract #
1026
Poster Bd #
107
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).
First Author: Sandra M. Swain
Poster
2021 ASCO Annual Meeting
MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study.
First Author: Yelena Y. Janjigian
Poster
2021 ASCO Annual Meeting
Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL).
First Author: Ariela Noy
Poster
2016 ASCO Annual Meeting
Safety and efficacy of lanreotide depot/autogel (LAN) in patients with lung NETs: The randomized, double-blind, placebo (PBO)-controlled phase III SPINET study.
First Author: Diane Lauren Reidy